Stocktoria
Moleculin Biotech, Inc. MBRX
Moleculin Biotech, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $15.9M | $17.7M | $19.5M | $19.0M | $14.4M | $12.8M | $11.0M | $9.7M | $4.5M | $1.5M |
| Operating income | -$25.1M | -$26.6M | -$29.6M | -$30.6M | -$23.0M | -$19.7M | -$17.5M | -$15.0M | -$8.7M | -$3.9M |
| Interest expense | — | — | — | — | — | — | — | — | $0 | $43,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | -$229,000 | $0 | $0 | $0 |
| Net income | -$33.6M | -$26.0M | -$29.8M | -$29.0M | -$15.9M | -$17.4M | -$13.2M | -$11.9M | -$9.8M | -$3.9M |
| Operating cash flow | -$22.7M | -$23.9M | -$23.6M | -$27.6M | -$19.0M | -$17.8M | -$17.2M | -$12.2M | -$7.3M | -$3.8M |
| Free cash flow | -$22.7M | -$23.9M | -$23.7M | -$27.7M | -$19.0M | -$18.1M | -$17.2M | -$12.6M | -$7.4M | -$3.8M |
| Cash & equivalents | $8.9M | $4.3M | $23.6M | $43.1M | $70.9M | $15.2M | $10.7M | $7.1M | $7.7M | $5.0M |
| Total assets | $22.1M | $16.9M | $38.2M | $57.4M | $84.1M | $29.0M | $25.2M | $19.6M | $19.5M | $16.4M |
| Total liabilities | $7.1M | $5.7M | $12.1M | $5.2M | $5.1M | $11.3M | $9.7M | $5.3M | $2.4M | $1.4M |
| Shareholders' equity | $15.0M | $11.2M | $30.9M | $52.2M | $79.0M | $17.8M | $15.6M | $14.3M | $17.1M | $15.0M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.